EU ‘Omnibus’ Simplification Shifting Medical-Device AI Deadlines: What Healthcare Organisations Need to Know to Protect Their Patients and Reputation
The European Union’s “Omnibus” package has brought about a wave of changes to the regulatory landscape for medical devices, particularly in relation to artificial intelligence (AI) claims. This development may be confusing for healthcare clients selling into or buying from the EU, but there is help available.
What is happening? The EU has revised its regulations regarding AI in medical devices by moving deadlines and implementing new guidelines for conformity assessment and market surveillance. Medical device manufacturers must now conduct a conformity assessment, which involves testing their product against harmonised standards to prove it meets safety and performance requirements. If the product passes, the manufacturer can affix the CE mark, indicating compliance with EU health, safety, and environmental protection standards.
Organisations in healthcare, insurance, and financial services that buy or sell AI-powered medical devices need to understand these changes because they affect their ability to ensure patient safety and protect their reputation. The revised regulations create a new level of scrutiny for AI claims, putting pressure on manufacturers to prove the accuracy and effectiveness of their products.
Why it demands action now: AI-powered medical devices must meet rigorous testing standards before being approved for use in clinical settings. Healthcare clients need to verify that these devices can accurately diagnose and treat patients without compromising care or safety. Compliance issues and potential product recalls can lead to reputational damage, loss of trust from customers, and even liability concerns.
To protect their patients and reputation, healthcare organisations should take the following steps:
1. Assess the impact of the revised regulations on their current medical device portfolio.
2. Review their compliance with harmonised standards for conformity assessment.
3. Evaluate potential risks associated with AI-powered devices in clinical settings.
4. Verify product claims against actual performance.
Straven & Co can help healthcare clients navigate these changes by providing independent validation services to examine AI decisions before they are acted on. This includes testing the proposed solution against the client’s real operations, its people, its governance and legal exposure, and the vendor’s actual claims, resulting in a plain verdict: proceed, proceed with conditions, or do not.
Straven & Co examines AI decisions before they are acted on: stravenandco.com